Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2017 Jul;15(7):677-688. doi: 10.1080/14787210.2017.1338139. Epub 2017 Jun 19.

Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?

Author information

1
a Louvain Drug Research Institute , Université catholique de Louvain , Brussels , Belgium.
2
b Department of Clinical Chemistry , Cliniques Universitaires St-Luc , Brussels , Belgium.
3
c Department of Intensive Care , Hôpital Erasme , Brussels , Belgium.
4
d Department of Infectious Diseases , Hôpital Erasme , Brussels , Belgium.
5
e Department of Intensive Care , Clinique St-Pierre , Ottignies , Belgium.
6
f Department of Intensive Care , Universitair Ziekenhuis Brussel , Brussels , Belgium.
7
g Department of Intensive Care , Cliniques Universitaires St-Luc , Brussels , Belgium.

Abstract

The pharmacokinetic/pharmacodynamic index determining β-lactam activity is the percentage of the dosing interval (%T) during which their free serum concentration remains above a critical threshold over the minimum inhibitory concentration (MIC). Regrettably, neither the value of %T nor that of the threshold are clearly defined for critically-ill patients. Areas covered: We review and assess the targets proposed for β-lactams in critical illness by screening the literature since 1997. Depending on the study intention (clinical cure vs. suppression of resistance), targets proposed range from 20%T > 1xMIC to 100%T > 5xMIC. Assessment and comparative analysis of their respective clinical efficacy suggest that a value of 100%T > 4xMIC may be needed. Simulation studies, however, show that this target will not be reached at first dose for the majority of critically-ill patients if using the most commonly recommended doses. Expert commentary: Considering that critically-ill patients are highly vulnerable and likely to experience antibiotic underexposure, and because effective initial treatment is a key determinant of clinical outcome, we support the use of a target of 100%T > 4xMIC, which could not only maximize efficacy but also minimize emergence of resistance. Clinical and microbiological studies are needed to test for the feasibility and effectiveness of reaching such a demanding target.

KEYWORDS:

PK/PD targets; critically-ill patients; first dose; maximal efficacy; Β-lactams

PMID:
28571493
DOI:
10.1080/14787210.2017.1338139
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center